New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Netherlands study establishes number of people in minimally conscious state after severe brain injury for the first time

Netherlands study establishes number of people in minimally conscious state after severe brain injury for the first time

byRadboud UniversityCredit: Unsplash/CC0 Public DomainEvery year, approximately 130,000 Dutch people suffer some form of acquired brain injury. The causes can be traumatic such as a fall or road
Neurology January 11,2024
Netherlands study establishes number of people in minimally conscious state after severe brain injury for the first time

Netherlands study establishes number of people in minimally conscious state after severe brain injury for the first time

byRadboud UniversityCredit: Unsplash/CC0 Public DomainEvery year, approximately 130,000 Dutch people suffer some form of acquired brain injury. The causes can be traumatic such as a fall or road
Neurology January 11,2024
New bladder cancer classification predicts treatment response

New bladder cancer classification predicts treatment response

byCedars-Sinai Medical CenterStudy design and gene signatures of patients with high-risk NMIBC according to BCG response subtypes (BRS). Credit:Science Translational Medicine(2023).
Oncology January 11,2024
New bladder cancer classification predicts treatment response

New bladder cancer classification predicts treatment response

byCedars-Sinai Medical CenterStudy design and gene signatures of patients with high-risk NMIBC according to BCG response subtypes (BRS). Credit:Science Translational Medicine(2023).
Oncology January 11,2024
How do we decide what to look at next? A computational model has the answer

How do we decide what to look at next? A computational model has the answer

byTechnical University of BerlinObject-based scanpath simulation in dynamic scenes. Credit: The image is derived from a frame of the field03 video of the VidCom dataset (Permission to Publish Co
Neurology January 11,2024
How do we decide what to look at next? A computational model has the answer

How do we decide what to look at next? A computational model has the answer

byTechnical University of BerlinObject-based scanpath simulation in dynamic scenes. Credit: The image is derived from a frame of the field03 video of the VidCom dataset (Permission to Publish Co
Neurology January 11,2024
Novel FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer

Novel FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer

by Vall d'Hebron Institute of OncologyIntermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain. The micrograph shows: Simple mucinous epithel
Oncology January 11,2024
Novel FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer

Novel FolRα-targeting antibody drug conjugate shows promise in recurrent epithelial ovarian cancer

by Vall d'Hebron Institute of OncologyIntermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain. The micrograph shows: Simple mucinous epithel
Oncology January 11,2024
New cancer therapy takes personalized medicine to a new level

New cancer therapy takes personalized medicine to a new level

by Karen WeintraubCredit: Unsplash/CC0 Public DomainPersonalized care has been a buzzword in medicine for years, but new research on cancer treatment is taking it to a new level.Detailed in a study pu
Oncology January 11,2024
New cancer therapy takes personalized medicine to a new level

New cancer therapy takes personalized medicine to a new level

by Karen WeintraubCredit: Unsplash/CC0 Public DomainPersonalized care has been a buzzword in medicine for years, but new research on cancer treatment is taking it to a new level.Detailed in a study pu
Oncology January 11,2024
New cancer 'tracer' promises to detect more tumors earlier

New cancer 'tracer' promises to detect more tumors earlier

by Ramona Czakert Franson,University of AlbertaCredit: Pixabay/CC0 Public DomainFor people waiting for imaging tests to diagnose neuroendocrine cancer, time is of the essence. Now, thanks to res
Oncology January 11,2024
New cancer 'tracer' promises to detect more tumors earlier

New cancer 'tracer' promises to detect more tumors earlier

by Ramona Czakert Franson,University of AlbertaCredit: Pixabay/CC0 Public DomainFor people waiting for imaging tests to diagnose neuroendocrine cancer, time is of the essence. Now, thanks to res
Oncology January 11,2024
New PET tracer shows promise for uPAR-targeted therapy of neuroendocrine neoplasms

New PET tracer shows promise for uPAR-targeted therapy of neuroendocrine neoplasms

by Society of Nuclear Medicine and Molecular ImagingGraphical abstract. Credit:Journal of Nuclear Medicine(2022). DOI: 10.2967/jnumed.121.263177A novel PET radiotracer can accurately asses
Oncology January 11,2024
New PET tracer shows promise for uPAR-targeted therapy of neuroendocrine neoplasms

New PET tracer shows promise for uPAR-targeted therapy of neuroendocrine neoplasms

by Society of Nuclear Medicine and Molecular ImagingGraphical abstract. Credit:Journal of Nuclear Medicine(2022). DOI: 10.2967/jnumed.121.263177A novel PET radiotracer can accurately asses
Oncology January 11,2024
New CAR T-cell immunotherapy shows promising results for treating blood cancer patients

New CAR T-cell immunotherapy shows promising results for treating blood cancer patients

byKing's College LondonUCART19 cellular kinetics and correlation with clinical response. A, Graphical representation of UCART19 kinetic profile in PB of patients with B-ALL in the CALM study
Oncology January 11,2024
New CAR T-cell immunotherapy shows promising results for treating blood cancer patients

New CAR T-cell immunotherapy shows promising results for treating blood cancer patients

byKing's College LondonUCART19 cellular kinetics and correlation with clinical response. A, Graphical representation of UCART19 kinetic profile in PB of patients with B-ALL in the CALM study
Oncology January 11,2024
New CAR T-cell therapy research shows potential in solid tumors

New CAR T-cell therapy research shows potential in solid tumors

by Peter MacCallum Cancer CenterCredit: Peter MacCallum Cancer CenterPeter Mac researchers have developed a new approach to chimeric antigen receptor (CAR) T-cell therapy which has proven effective in
Oncology January 11,2024
New CAR T-cell therapy research shows potential in solid tumors

New CAR T-cell therapy research shows potential in solid tumors

by Peter MacCallum Cancer CenterCredit: Peter MacCallum Cancer CenterPeter Mac researchers have developed a new approach to chimeric antigen receptor (CAR) T-cell therapy which has proven effective in
Oncology January 11,2024
New CAR T-cell strategy highly effective against small cell lung cancer in preclinical study

New CAR T-cell strategy highly effective against small cell lung cancer in preclinical study

by Roswell Park Comprehensive Cancer CenterCredit: Pixabay/CC0 Public DomainA new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (S
Oncology January 11,2024
New CAR T-cell strategy highly effective against small cell lung cancer in preclinical study

New CAR T-cell strategy highly effective against small cell lung cancer in preclinical study

by Roswell Park Comprehensive Cancer CenterCredit: Pixabay/CC0 Public DomainA new approach to chimeric antigen receptor T-cell (CAR T) therapy has shown great promise against small cell lung cancer (S
Oncology January 11,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com